Orthocell adds to Remplir use cases

WA biotech Orthocell has announced a promising new use case for its Remplir nerve regeneration product, this time in reducing post-surgical complications in prostate cancer sufferers.

The company told the market today its collagen wrap product, Remplir, had been used in 40 nerve-sparing robotic assisted radical prostatectomies surgeries around Australia.

Currently, around 80 per cent of men experience erectile dysfunction, and around 35 per cent suffer urinary incontinence, after a radical prostatectomy - largely due to damage to peripheral nerves surround the prostate.

And while enhanced surgical precision offered by robotic surgeries has assisted in lowering the after-effects, there remains a significant risk of nerve damage.

Orthocell managing director Paul Anderson said the latest use case highlighted Remplir's versatility as a product.

"Surgeons across multiple specialities - including orthopaedics, plastic and reconstructive surgery, and now urology - are increasingly adopting Remplir to simplify procedures, minimise scarring, and improve functional recovery," he said.

"This represents a significant step forward in Remplir's organic expansion into broader peripheral nerve repair applications and has the potential to substantially increase the device's global total addressable market."

Prostate cancer is the most diagnosed cancer among men in Australia with more than 26,000 new cases diagnosed last year alone.

There were around 12,000 RARP procedures performed using the da Vinci Surgical System in Australia last year.

The exclusive distributor of DVSS systems in Australia, New Zealand and Southeast Asia is Device Technologies - which is also Orthocell's distribution partner.

It comes as the company accelerates the launch of Remplir in Canada, and says it remains on schedule to submit its European and UK applications in the fourth quarter of this calendar year.

Orthocell shares jumped 10c to $1.22 per share following the announcement.